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Solubility Enhancement of Model Compounds

Abstract

by Lavanya Pitani
University of the Pacific
2017

Solubility is the amount of solute in the solvent system at phase equilibrium with
certain temperature and pressure. Many of the new chemical entities are lipophilic
molecules that require techniques to enhance solubility. Solubility enhancement can be
achieved by either physical and/or chemical modification of the drug. Various techniques
are available for solubility enhancement of poorly soluble drugs include particle size
reduction, salt formation, solid dispersions, use of surfactants, prodrug, crystal
modification, etc.
In this study, the three model drugs belong to BCS class II and IV having low
solubility with a certain range of physicochemical properties were studies in solubility
enhancement using fusion method, co-precipitation, nano-milling and spray drying
techniques. The two different polymers employed for solubility enhancement are PEG
8000 and PVP 40,000. Solubility was determined by Shake Flask method at the
temperature of 37±0.1 °C. The objective is to investigate the enhancement of solubility of
the three model drugs namely Glipizide, Carvedilol and Furosemide in 1:1, 1:5 and 1:10
drug-polymer ratios and are characterized by Differential Scanning Calorimetry (DSC).
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The Solubility of Glipizide was enhanced from 11.18 ± 1.78 µg/ml to 35.73 ± 0.04
µg/ml by 219 % increase with nano-milling technique at 1:5 ratio with PEG 8000 as carrier
whereas with PVP 40000 as carrier, 286 % increase in solubility to 43.26 ± 7.87 µg/ml was
observed at 1:1 ratio by fusion method. The solubility of Carvedilol was enhanced from
5.04 ± 0.55 µg/ml to 17.51 ± 0.94 µg/ml by 246 % at 1:5 ratio by fusion method with
PEG8000 as carrier and 2924 % enhancement in solubility to 152.70 ± 9.09 µg/ml at 1:10
ratio by nano-milling with PVP40000 as the carrier. Furosemide showed an increase in
solubility from 55.94 ± 2.48 µg/ml to 164.11 ± 9.18 µg/ml by 193 % at 1:10 ratio by nanomilling technique with PEG8000 as carrier whereas with PVP40000 as carrier, 444 %
increase was observed at 1:1 ratio by nano-milling technique with solubility of 304.52 ±
23.11 µg/ml. The data showed that the decrease in percentage crystallinity and enthalpy of
fusion of the model drugs upon implementing solubility enhancement techniques with the
effect of particle size and the carrier used resulted in the increase of aqueous solubility of
the model drugs.
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Chapter 1: Introduction
Solubility is defined as the amount of drug solute in a given volume of the solvent
system at a certain temperature, pressure and pH. [1] According to IUPAC, solubility is
defined as the analytical composition of a saturated solution, consisting of a designated
solute in a designated solvent system. A saturated solution is a solution in which the
dissolved solute is in an equilibrium with solute (solid phase), at an unambiguous
temperature. [1]
Solubility is one of the critical physicochemical properties of the drug that influences
the rate and extent of absorption. It is important for a drug to be in the form of an aqueous
solution at the site of absorption for it to be absorbed by the gastrointestinal (GI) tract. [1]
Solubility conduct of the drugs is one of the most challenging characteristics in formulation
development.
1.1 Solubility and its Significance in Drug Development
Poorly soluble drugs. A majority of active pharmaceutical ingredients that are being
developed (drug) are lipophilic with limited aqueous solubility leading to problems in
preclinical pharmacokinetic and toxicological investigations. Due to rapid advancement in
combinatorial chemistry, high-throughput screening this increase of poorly aqueous
soluble drugs have been observed [2].
Dose: Solubility ratio, a parameter that is used to identify poorly soluble drugs, is
defined as the volume of gastrointestinal fluids required to dissolve the administered dose.
If this volume exceeds available gastrointestinal fluids, then the drug is likely to have
solubility issues. [3] The USP has provided terms to describe the solubility parameters,
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which are quantitatively based on the number of parts of solvent and solute as shown in
Table 1.[3]

Table 1: USP Solubility Chart
Solubility at ambient temperature

Parts of solvent for 1 part of solute

Very soluble

Less than 1

Freely soluble

From 1-10

Soluble

From 10-30

Sparingly soluble

From 30-100

Slightly soluble

From 100-1,000

Very slightly soluble

From 1,000-10,000

Insoluble or practically insoluble

Greater than or equal to 10,000

Biopharmaceutical Classification System (BCS). Absorption in gastrointestinal
tract involves the breaking down of dosage form into primary particles when exposed to
gastrointestinal fluids. This step is called ‘disintegration’. The second step followed by
disintegration is ‘dissolution’, which involves the drug molecule to leave the solid form of
drug and enter into the form of a liquid solution, which is then followed by absorption
where the dissolved drug molecules later pass through the membrane of the gastrointestinal
tract to systemic circulation to reach its target site for pharmacological effect. [3,4] Due to
the importance of the interplay among solubility and permeability, the Biopharmaceutical
Classification System (BCS) was developed in 1995 to classify drugs depending on the
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absorption conduct. It has been categorized into 4 groups based on solubility and
permeability as shown in Table 2. [5] It defines that a drug, at its highest dose, is soluble in
250ml or less of aqueous media. A highly soluble drug has a pH that ranges between pH
1-7.5, while a poorly soluble drug presents an aqueous solubility of less than 100 µg/ml.

Table 2: Biopharmaceutical Classification System (BCS)
BCS class

Solubility

Permeability

Class I

High

High

Class II

Low

High

Class III

High

Low

Class IV

Low

Low

Class I: Drugs possess high solubility and permeability to cross bio-membranes. Gastric
motility and first pass effect are the only factors that affect the bioavailability of the drugs
and the dissolution rate for immediate release formulation of drugs dissolved 85 % in less
than 15 min.
Class II: Drugs have high permeability but low solubility as the rate-limiting step for API’s
for systemic absorption.
Class III: Drugs have high solubility and low permeability. API’s exhibit good solubility
profile and poor permeation across GI membrane having permeation as the rate-limiting
step in absorption and bioavailability.
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Class IV: Drugs have low solubility and low permeability with problems in oral
administration.
Increase in the solubility of BSC class II and IV by enhancement techniques results in an
increase of bioavailability. [6]
1.2 Factors Influencing Solubility
Melting point. Enthalpy is the thermodynamic measurement of heat content in the
system and enthalpy of fusion is defined as the heat required by the substance to change
from its solid state to liquid state. The temperature at which the phase transition from solid
to liquid state occurs is defined as the melting point. [6]
𝑙𝑜𝑔 𝑆𝑖 =

−𝛥𝑆𝑓
(𝑀𝑃 − 25)
1364

𝛥𝐻

where −𝛥𝑆𝑓 is the entropy of fusion ( 𝑇 𝑓 ) where 𝛥𝐻𝑓 is the enthalpy of fusion and 𝑇𝑓 is
𝑓

the freezing point [7]. The strength of the crystal lattice is indicated by melting point, which
is a physical property of the model drugs at a temperature where both the solid and liquid
phases are in equilibrium. It indicates the strength of the intermolecular solid-state
interactions, which is used to calculate aqueous solubility. Yalkowsky and Roseman
predicted solubility in the equation by simplifying the equation [8]:
log 𝑆𝑖 = −0.01(𝑀𝑃 − 25)
A higher melting point indicates strong solute-solute interactions for stable
crystalline compounds [9]. Hence, more energy is required to solubilize stable compounds
as they have strong intermolecular bonds with low solubility causing sharp melting points,
whereas, amorphous forms do not have a distinct melting point. Studies conducted by
Yalkowsky showed that the solubility is inversely proportional to melting point and
enthalpy [10].
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Partition coefficient. It is also denoted as log P and characterizes lipophilicity. It is
defined as the ratio of mole fraction concentration of solute in octanol and water phase.
Typically, an amount of log P that is greater than 5 indicates that the compound is highly
hydrophobic in nature and has an inverse relationship with aqueous solubility [11].
Many unionized organic solvent systems are quite miscible in octanol and give the
value of 0.5 upon simplification and the relationship is stated in the equation:
log 𝑆𝑤 = 0.5 − log 𝑃
With this equation, it clearly shows that negative correlation exists between log P
and solubility

[12]

. The solubility of the crystalline state in water is the product of the

solubility of solvent in water and the ideal solution given in the equation:
log 𝑆𝑤𝑐

𝑋𝑐
= log (𝑆𝑤 × liq )
𝑋

log 𝑆𝑤 + log 𝑋𝑢𝑖𝑑𝑒𝑎l
Upon simplification:
log 𝑆𝑤 = 0.5 − 0.01Δ𝑆𝑓𝑢𝑠 (𝑀𝑃 − 25) − log 𝑃
Particle size. The increase in surface area by the decrease in particle size, increases
the saturation solubility of the drug models. This is anticipated due to the increase of
curvature of the particle as interpreted by Ostwald Freundlich equation, where the
solubility increases due to the increase in the radius of the particle and applied to the
particle size less than 100 nm [13]. The drug with reduced particle size radius transforms
from crystalline to amorphous state with an increase in surface area.
Crystallinity. The repeating molecular patterns arranged in an orderly manner are
called crystalline forms and the solid materials with local molecular assemblies in absence
of crystal lattice are called amorphous materials. The materials have intermolecular forces
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in which crystalline intermolecular forces are more than that of amorphous forms

[14]

.

Crystalline forms show definite sharp melting points upon transformation from solids to a
liquid state. The non-crystalline state is thermodynamically stable with a tendency to
entropically drive solid forms to stable crystalline forms of higher free energy and
enhanced thermodynamic properties with higher molecular motion compared to crystalline
forms

[15]

. However, the amorphous forms cannot reach maximum solubility under

experimental condition due to strong driving force to recrystallize. Studies show that this
problem of recrystallization can be avoided by the addition of recrystallization inhibitors
[16]

.

1.3 Solubility Enhancement Strategies
Many physicochemical and physiological factors influence the saturation solubility
of the drug in the gastrointestinal tract. The solubility of a poorly aqueous soluble drug is
a challenging aspect of screening studies of new chemical entities and formulation
development. [17] Solubility and permeability are main parameters for in-vitro absorption as
it can be modified to enhance the solubility of the drug. Techniques like solid dispersions,
particle size reduction, eutectic mixtures, modification of crystal habits like cocrystallization, polymorphs and amorphous techniques, using of buffers, complexation, cosolvency, surface acting agents are few ways to increase the solubility by physical and
chemical modification. [18]
Chemical methods. Salt forms have shown to have enhanced solubility depending
on the pH of the medium. The conversion of acidic or basic drugs into water-soluble salt
forms leads to increase in solubility when in a gastric medium where it converts to free
acid or base which have low solubility and stability

[19]

. A complexation is an approach
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where two or more molecules associate due to various kinds of forces, hydrophobic or
hydrogen bonding between molecules to enhance solubility. The most common association
is observed between hydrophobic drug molecule with a central cavity to the hydrophilic
carrier on the outer surface

[20]

. Cyclodextrins (CD’s) are the most commonly used

complexing agents possessing the ability to take up the guest molecule into the internal
hydrophobic cavity of the CD’s, forming inclusion complexes [21].
Another approach is prodrug which is a chemical modification of the drug to
overcome barriers that hinder the drug delivery to reach the active site. It is bio-reversible
derivative, but the limitation is that it lacks in chemical stability of drug-promoiety linker
and degrades to forms secondary degradation pathways

[22]

. It involves in linking the

ionized group to the chemical structure of the drug to increase the solubility of the drug.
For example, Fosphenytoin, which is the prodrug of Phenytoin, shows more bioavailability
than Phenytoin [22,23].
Physical methods. Nanosuspension is the preparation of thermodynamically stable
insoluble or very slightly soluble solution in a given solvent by using one or more
amphiphilic components, which are known as surfactants [24]. The formation of submicron
colloidal suspensions with a pure drug that is stabilized by using surfactants are
nanosuspension. They enhance solubility due to increase in surface area. Surfactants lower
the surface tension at the air and liquid interface, leading to a rise in the surface area that
is available for the dissolution of the drug in the solvent. Homogenization, wet milling,
spray drying etc., are the various techniques that are used to make nanosuspensions [25].
Micronization is a technique, which increases the surface area with a decrease in
particle size causing an increase in the dissolution rate but not the equilibrium

[26]

. The
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decrease in the particle size may lead to solubility enhancement, where the Van der Waals
attraction that increases the surface area between the hydrophobic molecules causes a
decrease in size that may lead to agglomeration. Wettability is a challenge in micronization
and hence, the technique is unsuitable for drugs with high-dose numbers

[27]

. Ball mill,

fluidized micronization, ultrasonic size reduction, etc., are various techniques for
micronization used in the reduction of particle size. Sono-crystallization is a technique that
uses ultrasound frequencies ranging from 20-100kHz to break the crystalline form of the
drug [28,29]. This technique not only reduces the particle size but also enhances nucleation
rate [30].
Modification in crystal habit is classification of the solids as amorphous or
crystalline is done by analyzing the crystal structure. The amorphous form shows increased
solubility than that of crystalline due to the energy required to transform the crystal lattice
to non-crystalline solids [31]. The substance consisting one or more crystalline forms in it is
called a polymorph. The polymorphs that are unstable are called metastable polymorphs,
which consists of low melting points and increased solubility profile relative to the stable
forms [32].
There are two types of polymorphs based on the characteristics of melting point,
hardness and density. Monotropic polymorphs are those that are unstable at any
temperature and pressure. Enantiotropic polymorphs are the forms where the change is
reversible to other forms with a change in temperature and pressure [33,34].
Another type of polymorph is the form that contains water as solvent called pseudo
polymorphs. These are more soluble in water and requires less energy to break the lattice
compared to solvates [35].
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Drug dispersion in the carrier is one of the most commonly used technique for the
enhancement of drug to enhance its solubility is solid dispersion. It is defined as the
dispersion of the hydrophobic drug in hydrophilic biologically inert matrix

[35-37]

. But the

common challenge with this method is that there is a chance of possible drugrecrystallization on long-term storage. Additionally, moisture plays a vital role in the
enhancement of drug mobility. There are five types of solid dispersion, which is classified
as simple eutectic mixture, solid solution, complex formation, amorphous precipitation,
glass solution/suspension and any of the combinations. A simple eutectic mixture is
nothing but a mixture that is soluble in its liquid state but immiscible in its solid state [38].
Solid solutions are those that, irrespective of the components used, results in a single
phase and are continuous and discontinuous solutions, depending on the drug and the
carrier. The continuous solutions are miscible when formed with two miscible proportions
in any proportions. However, a discontinuous solution is limited to miscibility of only 1
component

[39]

. Glass solutions/suspensions are the types of solid dispersions, where the

drug is suspended or dissolved into a glassy form that entraps the drug molecule into the
matrix. These dispersions are stable as they are formed by dispersing the crystalline drug
in an amorphous carrier and are of type IV dispersions

[40]

. Using DSC thermograph, the

melting point and glass transition temperature can be observed. Type V dispersions are the
amorphous drug clusters that are subsumed into the carrier. These are metastable and if the
clusters are too big, they form nuclei that promote rapid crystallization and increase in
growth. But, when clusters are small, enough drugs cannot be incorporated to recrystallize.
There are various techniques that can be used to prepare solid dispersion.
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Fusion solvent method is used for solid dispersion where the drug is first added and
dissolved in a suitable solvent when the prepared solvent mixture is in a molten state. Later,
it is cooled to acquire the product

[41]

. Hot melt extrusion is a process similar to fusion

method except that the mixing of drug and the carrier is performed by the extruder.
Hot melt/fusion method is the physical mixture of the hydrophobic drug molecule
is melted with hydrophilic carrier together and cooled simultaneously in an ice bath. The
obtained hard mass is crushed, pulverized, sieved and stored in a desiccator. The stability
of both the components are taken into consideration as the melting point depends on the
composition including a selection of carrier, the weight fraction of drug and miscibility of
both the components in molten forms [42].
The limitations of this method are that it is suitable only if the drug and polymer are
compatible with each other and forms a homogeneous mixture at the heating temperature
of percent formation of two incompatible liquid phases or suspensions in the heated
mixture

[43]

. This can be overcome by using surfactants. During cooling, when the drug-

matrix miscibility changes, the mixture might produce a phase separation that can be solved
when done slowly, forming a crystalline drug. Formation of the crystalline drug is a
problem that can be overcome by forming an amorphous dispersion by speeding up the
cooling rate. It is unsuitable for compositions where the carrier is high-melting solid and is
sensitive to heat.
Co-precipitation method is the technique with both the drug and the polymer are
soluble in a common solvent. The polymer is first dispersed in the solvent and the drug is
added to it, to form a homogeneous mixture. Later, the solvent is removed by evaporation
by vacuum, under a temperature higher than the room temperature. The solvent can also
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be removed by freeze drying or by spray drying [44]. The advantage of this technique is that
the solvent can be removed at a lower temperature; it is useful when using thermolabile
drugs. However, it is difficult to completely evaporate the solvent from the composition,
which is a limitation.
The challenges and limitations faced when performing solvent evaporation
technique are that it is difficult to mix drug in the polymer to one solution with different
polarity and prevent phase separation in the time of removal of the solvent.
Nano-milling is the technique with the active pharmaceutical ingredient and carrier
is reduced to a submicron range and is aqueously dispersed. These are then processed in
wet media milling following the principle of attrition [45]. The advantage of this technique
is that the solubility and dissolution are improved upon nanosizing. The main challenge is
the development of this method, separation of nanocrystals from solution as the particles
are in the nanometer range.
Wet-milling is comminuted by milling media in the presence of surface stabilizers
and drug. Depending on the number of contact points, the stress intensity particle size is
determined. Stress intensity is the function of kinetic energy involved in the process of
grinding beads, where the number of contact points is obtained by a grinding media

[46]

.

For example, the number of contact points increases by using smaller grinding media. The
presence of stabilizers in wet-milling is mandatory as the high-energy wet mill process
leads to a thermodynamically unstable aqueous nanosuspension. The drive shaft attached
to the rotating disk provides energy to the zirconium beads to break the crystals, using
compression-shear action. This technique is most commonly used for nanosizing. The
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Dyno-mill consists of a grinding container, feed pump, grinding beads, driving shaft,
dynamic gap separator, agitator disc, pressure gauge and a cooling cylinder.
The advantage of nanosuspension preparation by wet-milling is that it improves the
rate of dissolution with reduced variability, leading to increased bioavailability. Some
studies have shown that the nanoparticles can increase bioavailability and passive
absorption [47] and in some, the decrease in dose and increase in bioavailability is compared
to micron-sized API [48].
Spray drying technique contain dry powder that is incorporated into nanosuspension
that can be used to prepare solid dosage forms like tablets, capsules, pellets etc. It can be
achieved by spray drying process where the drug is embedded in a carrier matrix, to
enhance solubility and dissolution [49].
Spray drying is based on the principle of pneumatic drying where the drying particles
are entrained and carried in a high-velocity gas stream and the solvent is removed from the
liquid stream. The liquid droplets reach a temperature higher than the wet bulb temperature
of the gas when it comes in contact with the hot gas. [50]. Formation of a tough shell takes
place by the evaporation of the surface liquid and the process of drying occurs when the
liquid from the interior of the droplet starts to diffuse through the shell at a slower rate than
the transfer of heat from the surface of the shell to the droplet’s interior. The liquid below
the shell lining evaporates at a rapid rate and causes a buildup of heat beneath it, resulting
in internal pressure and swelling of droplets. This produces a thinner shell and faster
diffusion of the liquid from the interior of the shell

[51]

. Hence, spray dried products have

intact spheres, rupture hollow spheres or sphere with bulbs and fragments. Non-elastic
shells usually erupt producing fragments or bulb-like structures on the spheres [52].
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The components of spray dryer include feed pump, atomizer, drying chamber,
cyclone separator, a product collector, aspirator and filter. The liquid feed is sent to the
atomizer at an adjusted rate so that each droplet is dried completely before it comes in
contact with the walls of the drying chamber, preventing excessive heat than necessary in
the drying process. The atomizer like pneumatic, pressure or spinning disc, delivers feed
into fine droplets into a drying chamber where the feed is broken into droplets with the
help of high-velocity gas [53]. These, in return, produce smaller particles and encounters hot
gas. This hot air is supplied by blowing air over a heat exchanger and the particles are
separated by a cyclone separator where the solid dried product is collected. The dried
product on the walls of the drying chamber is called chamber product. It is usually coarser
in size and more exposed to heat than usual.
Factors affecting spray drying is the feed rate adjusted accordingly and is indicated
by an outlet air temperature and visual inspection. The inlet temperature of drying air is the
temperature required to dry the medium when it encounters the feed

[54]

and the feed

temperature determines the ability to dry and remove the solvent in unit time. The outlet
temperature depends on the inlet temperature that is measured when the air enters the
drying chamber. For example, the change in inlet temperature results in different glassy
state products of 4-O-(4-methoxyphenyl) Acetyltylosin

[55]

. Also, when the feed rate is

increased, the outlet temperature drops and the material builds up on the walls of drying
chamber [54]. During spraying, drying gas flow rate determines the amount of air required
to dry the samples per unit time effecting the drying level and its separation in the separator
[56]

. When the drying air flow is low, it requires a longer duration for the particle to dry.
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Spray drying is commonly used to remove the solvents from the liquid stream and
dry even the most thermolabile fluids without degrading the composition of the samples.
This technique is initially used for extracting active raw materials from the plants [44]. The
tablet, which is a spray dried lactose, used for making tablets in the direct compression
process, in turn, shows good compression properties of the powder [57]. It is used to change
the melting points of the APIs to avoid crystallization in the tabletting process. It is also
used to obtain particles with desired size and morphology, to enhance aqueous solubility,
apparent solubility and dissolution rate. Spray drying produces appropriate particle size
that can be administered via ophthalmic, inhalation powders and vaccines and preparation
of self-emulsifying systems for a good release and enhanced bioavailability of drugs. They
can be used as protective agents for drugs that are unstable in the gastrointestinal
environment.
Re-dispersible dry emulsions used in the small intestine to decrease metabolism and
increase oral absorption can be prepared by this technique

[58]

. It is also used to produce

modified releasing tablets and to formulate protein drugs. Nevertheless, little success has
been achieved as the low final yield is a major problem and aggregation causes proteins to
unfold that may lead to denaturation. The potential and applications in protein drying and
preparations using spray drying methodology has not been fully explored.
1.4 Solid-State Transitions
Drugs are present in a high degree of order that is the vital property of the physical
state. They are present in crystalline, lattice-like and non-crystalline types

[59]

. This

attributes to the higher melting point as they possess strong bonds. The molecular shape of
chemical groups with intermolecular bonding like hydrogen bonding, dipole-dipole
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interaction and charge transfers is responsible for the packing arrangement of these types.
These features account for melting points of these crystals

[60]

. The components that are

hard and brittle contain high melting points as they contain crystal lattice. They are
thermodynamically unstable in the amorphous forms but have a tendency to entropically
drive to stabilize crystalline conditions. However, the diffusional process slows down the
process of recrystallization. The free energy containing amorphous forms is much higher
than crystalline forms [61].
Amorphous forms, also known as disordered materials, lack crystal lattice. They
contain intermolecular forces but lack periodicity with different physicochemical
properties like melting point, solubility, enthalpy, density, etc [62]. The amorphous materials
help in retaining the state at room or body temperature, for instance, drugs with
polyethylene glycol, polyvinyl pyrrolidone, etc. [63]. Amorphous forms have an advantage
of being partially amorphous for preparation of dosage forms.
Influence of free energy on solubility is that amorphous forms have higher Gibbs
free energy and do not require additional energy to break crystal lattice whereas, in case of
crystalline materials, the drugs need to overcome the energy required to break the crystal
lattice arrangement and enter aqueous solution

[64]

. Hence, this leads to an increase in

solubility when the drug is in amorphous form rather than in crystalline. However, the
amorphous materials are unstable due to Gibbs free energy and hence try to alter back into
crystalline stable forms over some period of changing the properties.
1.5 Estimation of Aqueous Solubility
The therapeutic efficacy is determined by the aqueous solubility and it is one of the
vital physicochemical properties based on the non-experimental structural parameter. Low
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solubility APIs have been used to obtain solubility enhanced formulations, by increasing
and implementing solubility enhancement techniques

[65]

. Aqueous solubility provides an

estimation of enhanced solubility information prior to performing solubility enhancement
techniques, in addition to its influence on the factors or parameters that helped in the
enhancement

[66]

. This provides a general idea of the compound and excipient selection,

with suitable properties and conditions, to acquire the desired solubility which benefits
economically reduces the wastage of supply in the early development.
1.6 Carriers Used for Solid Dispersion
Carriers are polymers or recrystallization inhibitors, which are hydrophilic
substances used for solid dispersions, primarily classified as polymers of sugar polyols,
surfactants, organic acid and their derivatives [67]. Examples of polymers of sugar polyols
contain mannitol, sorbitol and chitosan with its derivative chitin. Apart from PEG and PVP
polymers, which are most commonly used, Eudragit, Hydroxypropyl cellulose and
Hydroxypropyl methylcellulose are other examples of polymers. Surfactants, which
include Sodium Lauryl Sulfate (SLS) or Tween 80, are amphiphilic in nature and contain
both hydrophilic and hydrophobic moieties that help in enhancing solubility with limited
toxicities. [68].
Polyethylene glycols (PEG) are ethylene oxide oligomers that can be used as a carrier
to enhance solubility, wettability and dissolution of the active pharmaceutical agents. Due
to their low melting point that ranges from 53 °C to 63 °C, they can be used easily to
produce solid dispersions. PEG is available in different grades, depending on the molecular
weights that range from 200 to 300,000, which helps in differentiating them from
polyoxyethylene and polyethylene oxide

[69]

. PEGs with the molecular weight 600 are
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liquids, and those that range from 800 to 1500 are semisolids; PEGs with a molecular
weight that range from 2000-6000 are waxy and above 6000, are crystal, at the room
temperature. The molecular weights above 1500 are usually utilized in solid dispersion
preparation as the aqueous solubility and viscosity is in direct relationship with the
molecular weight of PEG. Viscosity is directly proportional to the molecular weight of
PEG and molecular weight is inversely proportional to aqueous solubility. The advantage
of PEG is that it can be soluble in almost all the organic solvents and hence can be used as
a pharmaceutical excipient [70].
Polyvinyl pyrrolidone (PVP) are the hydrophilic carriers, which are synthetic linear
polymeric lactam, used in gastrointestinal preparations. They are soluble in almost all
organic solvents and are formed by polymerization of vinylpyrrolidone. They are
amorphous and are prepared in a variety of molecular weights, expressed as K-value, based
on the viscosity measurement. Molecular weights of PVP is directly proportional to glass
transition temperature (Tg) of linear PVP.
PVP shows anti-plasticizing effect causing surface absorption and a steric hindrance
for crystal growth and nucleation inhibiting recrystallization of the drugs [71]. Hence PVP
shows good solubility and wettability, which makes it a common choice of carrier to be
used in solid dispersions.
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Chapter 2: Research Aims
The solubility of poorly soluble drugs has been a challenging factor in the
development of the drug, although several techniques are established to enhance the
aqueous solubility of the drug at laboratory scale. Due to the limitation in the utility in
industrial-scale production, there is a necessity to identify robust, reproducible and reliable
technology that can be applied to an insoluble drug. Although solid dispersions and particle
size reductions have been showing improved solubility, the basic mechanism underlying
for the increase has not been explained elaborately.
The primary objective of this study is to prepare the compositions and physical
mixtures of the model drugs with polymer stabilizers, to increase the aqueous solubility
using solid dispersions and particle size reduction techniques. The aim is to determine the
aqueous solubility using solid dispersion techniques. During these experiments, all the
parameters except the model drugs and composition of the polymers were maintained
constant. Methanol was used as the common solvent in co-precipitation technique.
The secondary objective is to compare the techniques and characterize the solid-state
characters of composites using DSC, to investigate the reasons for the increase in solubility.
The solubility studies were conducted at 37 °C in filtered distilled water. The enthalpy of
compositions was compared to a model pure drug from DSC thermograms and the change
in crystallinity was determined.
The third objective is to determine the method that exhibits significant enhancement
of aqueous solubility of each model drug. For this, the aqueous solubility of Glipizide,
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Furosemide and Carvedilol determined from the compositions with fusion method, coprecipitation, nano-milling and spray drying techniques and was compared.
The significance of this research is to determine the influence of method of
preparation and properties of the excipients used on the increase in the aqueous solubility.
The increase in aqueous solubility over the physical mixtures indicates that the techniques
improve the solubility of the drug.
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Chapter 3: Materials and Methods
The first objective of the research was to prepare a solid dispersion by using three
model compounds with a range of properties and determine their solubility.
3.1 Materials
Glipizide, Furosemide and Carvedilol were obtained from Spectrum Chemicals (NJ,
USA), Polyethylene glycol 8000 from Dow Chemical Company, Polyvinyl pyrrolidone
40000 from Fisher Scientific (NJ). Methanol used was of analytical grade. Deionized water
was used for saturated solubility studies and 0.22µm nylon syringe filters were used to
filter the supernatant solution from solubility studies. Furosemide, Glipizide and Carvedilol
are the three model drugs selected from BCS class II and IV drugs. The physicochemical
properties of the model drugs are shown in Table 3.

Table 3. Physicochemical Properties of Model Drugs
Model drugs

BCS Class

Molecular

Log P

pKa

MP (°C)

weight
Furosemide

IV

330.7

2.03

4.25

206

Glipizide

II

445.5

1.91

5.9

215.89

Carvedilol

II

406.4

4.19

8.74

116.64-120.24
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3.2 Methods
Different compositions like physical mixtures were prepared and techniques like
fusion method, co-precipitation, nano-milling and spray drying were used, in addition to 2
polymers namely PEG 8000 and PVP 40,000 at 1:1, 1:5 and 1:10 drug-polymer ratios.
The physical mixtures compositions of Glipizide, Furosemide and Carvedilol were
prepared by thoroughly mixing of drug with the polymer in a mortar until a homogeneous
mixture was obtained.
Fusion method is a technique in which the drug-polymer ratios of 1:1, 1:5 and 1:10
were weighed and triturated in to achieve a proportionately mixed physical mixture. The
mixture was then melted on a hot plate above the melting points of the model drugs. This
resulted in the formation of a molten mixture, which was then rapidly cooled by placing
over an ice bath for 5 minutes and stirring vigorously, until they solidify. All the
experiments were carried out in triplicates (n=3) and analyzed further for solubility.
Co-precipitation technique is a technique in which the co-precipitates were prepared
by first weighing the drug and polymer at predetermined ratios and then transferring them
into the beaker containing methanol. The polymer was added to methanol and mixed well,
before adding the drug. The drug was then added, transferred to glass scintillation vial and
methanol (solvent) evaporated in a rotary evaporator (Rotavapor R300, Buchi,
Switzerland) at a reduced pressure and temperature. The resulting co-precipitate
compositions were kept on a hot plate at a low temperature for the evaporation of the
residual solvent. The final product was scraped, pulverized and stored in a desiccator for
analysis of solubility.
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Nano-milling contains nanosuspension prepared by media milling using 120 ml of
Zirconium oxide beads of size 0.5 mm in Dyno mill Multilab (Glenmills, Clifton, NJ) at a
speed of 4180 rpm for 1 hour. The nanosuspension was then frozen overnight at -80 °C and
dried to yield dry nanoparticle powder for saturated solubility studies.
Spray drying technique is performed where the PVP 40,000 polymer and the drugs
were weighed accurately in the desired ratios of 1:1 of Glipizide and Furosemide; 1:10 of
Carvedilol was dissolved in methanol. The solution was then spray dried using SONOtech
nozzle system Buchi B290 spray dryer. The drug loading was 5 % (w/v) of Glipizide, 7.5
% (w/v) of Furosemide and 7.5 % (w/v) of Carvedilol. The following table shows the
parameters of the different formulations:

Table 4. Parameters for Spray Drying of Model Drugs
Spray Parameters

Glipizide

Furosemide

Carvedilol

Drying air (m3/min)

0.5

0.2

0.45

Inlet temperature (°C)

150

160

145

Outlet temperature

90

89

90

4.3

5.4

3.6

0.15

0.2

0.15

(°C)
Feed flow rate
(ml/min)
Atomizing air (MPa)
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Chapter 4: Characterization of Compositions
4.1 Differential Scanning Calorimetry (DSC)
The compositions and physical mixtures were subjected to thermal analysis and
compared to pure drug using DSC 6200, SII EXSTAR 6000 with Muse measurement
COM2 software. To calibrate the temperature and enthalpy values of samples, high purity
indium was used and the samples were sealed in aluminum pans. An empty aluminum pan
was used as the reference standard. The samples of approximately 3 mg were weighed and
were scanned and analyzed at a temperature range of -10 °C to 350 °C with a heating rate
of 10 °C/min using nitrogen as the blanket gas.
4.2 Results
To determine solid changes and compatibility studies, DSC was extensively used
and was a sensitive method used for the detection of solid phase transition. The melting
point of crystalline compounds depends on the intermolecular forces between molecules
that hold together in forming a crystal [72-73]. When the intermolecular bonds break, it shows
an endothermic peak obtaining a melting point of the sample, whereas, in non-crystalline
samples, the formation of an endothermic peak is not observed. The crystallinity of the
compound is determined by the presence or absence of endothermic peak [74]. The polymer
PEG 8000 showed an endothermic peak at 67.24 °C with an enthalpy of fusion of -301.4
J/g whereas PVP 40,000 showed broad spectrum and melting point at 175.55 °C with an
enthalpy of fusion of -29.5 J/g due to the presence of residual moisture in PVP.
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The DSC of Glipizide showed melting of the drug with a characteristic endothermic
peak at 216.53 °C with an enthalpy of fusion of -120.8 J/g, indicating that Glipizide was in
a crystalline state in a pure solid form, which was consistent with the literature

[75]

. The

physical mixtures of Glipizide with PEG 8000 in 1:1 ratio showed an endothermic peak at
204.52 °C whereas 1:5 and 1:10 ratios of physical mixtures did not show any endothermic
peaks at the temperature of Glipizide as shown in Figure 1 and 3. The melting point
decreased, which may attribute to PEG 8000 acting as an impurity to Glipizide in 1:1 ratio.
In the fusion method, drug peak was observed at 204.55 °C and 186.24 °C for 1:1 and 1:5
respectively, with an enthalpy of -19.3 J/g and -5.2 J/g but without a peak in 1:10 ratio as
shown in Figures 1-3. In co-precipitation technique, DSC showed an endothermic peak at
205.0 °C with an enthalpy of -44.1 J/g in 1:1 ratio and 207.57 °C with an enthalpy of -2.7
J/g for 1:5 ratio. In nano-milling, 1:1 ratio showed an endothermic peak of the drug at
194.36 °C with an enthalpy of -4 J/g and 1:10 had a drug peak at 197.39 °C with an enthalpy
of -6.5 J/g as shown in Figure 3. There was an absence of an endothermic peak in 1:10 ratio
and in nano-milled samples and also in 1:5 ratio of co-precipitation. The disappearance of
the peak may be due to the high concentration of PEG 8000 in the sample, which leads the
drug to below the detection limit and more dilute drug in the polymer or in the formation
of amorphous form from crystalline. The absence of endothermic peaks confirms that the
lack of crystalline drug in significant amounts.
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Figure 1. Thermograms of Glipizide-PEG8000 Composites from Fusion, Co-precipitation
and Nano-milling Methods at 1:1 Ratio

Figure 2. Thermograms of Glipizide-PEG8000 Composites from Fusion, Co-precipitation
and Nano-milling Methods at 1:5 Ratio
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Figure 3. Thermograms of Glipizide-PEG8000 Composites from Fusion, Co-precipitation
and Nano-milling Methods at 1:10 Ratio

The physical mixture of Glipizide and PVP 40,000 showed the melting point of
Glipizide to be at 204.76 °C, 204.58 °C and 210.31 °C, at drug-polymer ratios of 1:1, 1:5
and 1:10 respectively. In fusion method, Glipizide and PVP 40,000 with a ratio of 1:1
showed drug melting peak at 192.75 °C with an enthalpy of -6.9 J/g as shown in Figure 4
and 1:10 with -0.5 J/g at 163.46 °C endothermic peaks as shown in Figure 6. In coprecipitation technique with 1:5 ratio presented a peak at 175.03 °C with an enthalpy of 10 J/g as shown in Figure 5 and 1:10 ratio drug endothermic peak at 179.6 °C with an
enthalpy of -8.6 J/g. The endothermic peak at 169.01 °C and 165.6 °C with an enthalpy of
-10 J/g and -7.3 J/g for 1:5 and 1:10 ratios respectively. In 1:1 ratio of nano-mill technique
followed by degradation, there was no drug endothermic peak observed whereas in coprecipitation there was an absence at 1:1 ratio and at 1:5 ratio in fusion method. In spray
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drying technique, Composites at 1:1 ratio showed an endothermic peak at 146.13 °C with
enthalpy -9 J/g.

Figure 4. Thermograms of Glipizide-PVP40000 Composites from Fusion, Coprecipitation, Nano-milling and Spray drying Methods at 1:1 Ratio
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Figure 5. Thermograms of Glipizide-PVP40000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:5 Ratio

Figure 6. Thermograms of Glipizide-PVP40000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:10 Ratio
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The thermogram of Carvedilol showed an endothermic peak at 120.2 °C with an
enthalpy of -97 J/g consistent with the literature [76]. The physical mixtures of Carvedilol
and PEG 8000 with ratios of 1:1 showed an endothermic melting peak at 116.88 °C and
enthalpy of -22 J/g, whereas, at 1:5 and 1:10 ratios, composited did not show any drug
melting peak. In fusion method composites at 1:1 ratio as shown in Figure 7, the
endothermic peak was observed at 102.46 °C with an enthalpy of -23.4 J/g and in
coprecipitation at 114.41 °C with an enthalpy of -29 J/g. The melting peak of Carvedilol
was absent in 1:5 and 1:10 of fusion method and co-precipitation as shown in Figure 8 and
9. The composited from nano-milling technique at all the ratios did not exhibit any
endothermic peak.

Figure 7. Thermograms of Carvedilol-PEG8000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:1 Ratio
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Figure 8. Thermograms of Carvedilol-PEG8000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:5 Ratio

Figure 9. Thermograms of Carvedilol-PEG8000 composites from Fusion, Coprecipitation and Nano-milling Methods at 1:10 Ratio
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The physical mixture of Carvedilol with PVP 40,000 of ratios 1:1 and 1:5 showed
an endothermic peak at 116.88 °C and 118.09 °C, with an enthalpy of fusion of -4.1 J/g
and -3.3 J/g respectively. No endothermic peak was observed at 1:10 ratio. In fusion
method, co-precipitation, nano-milling and spray drying techniques, no drug peak was
detected as shown in Figures 10-12.

Figure 10. Thermograms of Carvedilol-PVP40000 composites from Fusion, Coprecipitation and Nano-milling Methods at 1:1 Ratio
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Figure 11. Thermograms of Carvedilol-PVP40000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:5 Ratio

Figure 12. Thermograms of Carvedilol-PVP40000 composites from Fusion, Coprecipitation, Nano-milling and Spray drying Methods at 1:10 Ratio
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The thermogram of Furosemide showed an exothermic peak at 226.57 °C with an
enthalpy of fusion of -2 J/g. The formation of exothermic peak could be the reason of
recrystallization of melted furosemide. The melting, recrystallization, and degradation of
Furosemide were observed at 229.65 °C with an enthalpy of 6.7 J/g

[77]

. The DSC

thermograms of a physical mixture of Furosemide and PEG 8000 exhibited an absence of
drug peak. In fusion method, 1:1 ratio presented an endothermic peak at 213.47 °C with an
enthalpy of -5.4 J/g. At 1:5 and 1:10 ratios showed no endothermic peak. For Furosemide,
no endothermic peaks were observed in fusion method, co-precipitation, and nano-milling
as shown in Figures 13-15.

Figure 13. Thermograms of Furosemide-PEG8000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:1 Ratio

49

Figure 14. Thermograms of Furosemide-PEG8000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:5 Ratio

Figure 15. Thermograms of Furosemide-PEG8000 composites from Fusion, Coprecipitation and Nano-milling Methods at 1:10 Ratio
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The physical mixture of Furosemide and PVP 40,000 did not show any endothermic
peaks. In co-precipitation method at 1:1 ratio, an endothermic peak was observed at 142
°C with an enthalpy of -0.8 J/g, whereas, 1:1 ratio of spray dried technique showed a peak
at 141.2 °C with an enthalpy of -1.8 J/g as shown in Figure 16. There was an absence of an
endothermic peak in fusion method, nano-milling and co-precipitation at 1:5 and 1:10
ratios as shown in Figures 17 and 18.

Figure 16. Thermograms of Furosemide-PVP40000 Composites from Fusion, Coprecipitation, Spray drying and Nano-milling Methods at 1:1 Ratio
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Figure 17. Thermograms of Furosemide-PVP40000 Composites from Fusion, Coprecipitation and Nano-milling Methods at 1:5 Ratio

Figure18. Thermograms of Furosemide-PVP40000 composites from Fusion, Coprecipitation and Nano-milling Methods at 1:10 Ratio
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The complete absence of endothermic peak indicated that the drug could not be
detected as the drug quantity is small when compared to the polymer. The other possibility
is that a modification took place in the crystalline structure of the drug when compared
with the physical mixture and compositions obtained with different techniques.
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Chapter 5: Aqueous Solubility of Model Compounds
Solubility was determined by traditional shake flask method, where the samples were
added to 10 mL of distilled water in scintillation vial until saturation and the existing solid
were observed. These were maintained at a temperature of 37 °C and were constantly shook
inside a water bath. Samples were withdrawn and filtered using 0.45 µm nylon filters and
the filter sample was then analyzed using HPLC until the constant concentration of drug
that is dissolved was obtained. This experiment was done in a triplicate.
5.1 HPLC
HPLC analysis was performed using isocratic gradients and columns, namely C8
and C18. HPLC conditions of different model drugs are mentioned in Table 5. The flow
rate of all the formulations was 1 ml/min and a UV detector, suitable for model drugs, set
at different wavelengths, was used for detection. The collected solubility samples were
diluted and analyzed. The peak area was recorded, and the concentration was determined.
5.2 Statistical analysis
Analysis of Variance and student t-test was performed using Microsoft Excel 2016 and the
significance level which is (α = 0.05) was based on the probability value (p < 0.05)
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Table 5. Chromatographic Conditions for Analysis of Model Drugs
Model drug Mobile phase

Wavelength

Retention

Column

(nm)

time (min)

dimensions /
temperature
(°C)

Glipizide

pH

6

Monobasic

sodium 225

6.79

C18 column

phosphate buffer: Methanol

4.6x150mm

(55:45)

3.5µm
/ 25°

Carvedilol

ACN:

(pH

2

monobasic 240

5.38

potassium phosphate) (31:69)

C8

column

4.6x100mm
3.5µm/ 55°

Furosemide

TFA: water: glacial acetic acid
(30:70:1)

272

4.35

C18 column
4.6x150mm
3.5µm / 25°

Results. The saturated solubility studies were determined in distilled water at 37 °C.
Carvedilol, BCS class II drug, had a very low solubility when compared to Glipizide and
Furosemide. The solubility of physical mixtures was compared to pure drug solubility
studies.
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Table 6. Comparison of Solubility of Model Drugs
PEG8000
Composition

PVP40000

Glipizide

Carvedilol

Furosemid

Glipizide

Carvedil

Furosemid

(µg/ml)

(µg/ml)

e (µg/ml)

(µg/ml)

ol

e (µg/ml)

(µg/ml)
Drug

R

11.18±1.7

5.04±0.55

8
Physical

1:1

mixture

12.38±0.9

5.23±0.07

9
1:5

13.95±2.2

5.37±0.22

7
1:10

14.33±1.6

6.03±0.67

9
Fusion

1:1

method
1:5

1:10

11.18±1.7

5.04±1.2

55.94±2.4

8

8

2

8

55.98±1.0

14.32±2.6

6.38±1.2

61.98±2.5

1

2

8

2

60.97±2.2

12.88±0.4

5.74±0.2

70.17±3.1

9

3

7

1

63.89 ±

11.30±1.2

6.59±0.3

67.42±5.7

5.29

1

3

6

12.90±2.1

16.16±0.8

64.21 ±

43.26±7.8

29.46±6.

132.36±9.

4

0

3.48

7
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94

25.57±1.9

17.51±0.9

69.17 ±

39.15±1.2

1

4

2.43

8

06

.78

24.66±2.5

12.7±0.55

76.10 ±

19.96±2.8

62.44±1

100.70±5.

5.24

9

7.69
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9
1:1

55.94±2.4

48.28±6. 128.42±24

27.03±4.3

11.87±1.4

74.56 ±

25.30±3.7

24.41±4.

93.53±7.3

3

8

4.10

7
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3
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1:5

27.56±2.9

11.20±1.8

72.59 ±

43.00±7.1

53.41±6. 281.37±39

7

2

4.81

0

06

.68

35.39±2.4

11.59±0.3

72.86 ±

22.81±2.1

104.30±

192.48±30

6

0

6.61

5

9.28

.67

23.73±1.5

1.95±0.21

134.96 ±

40.37±4.8

1.20

3

6

.11

163.86±10

31.08±4.7

60.78±1

287.48±11
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2

1.99

.72

164.11±9.

8.23 ±

152.70±

232.21±24

18

1.22

9.09

.04

-

15.97±3.1

-

182.52±6.

Coprecipitati
1:10
on

Nano-

1:1

milling

4
1:5

35.73±0.0

2.05±0.23

4
1:10

24.11±0.9

2.14±0.28

1
Spray

1:1

-

-

drying

2.80±0.3 304.52±23

1
1:10

-

-

-

-

95
67.42 ±

-

1.22

The aqueous solubility of the model drugs as shown in table 6, indicated that the
optimum solubility enhancement was achieved at different (drug: polymer) ratios. A
further increase of polymer excipient did not enhance the drug solubility, at times reduced
it

[78]

. PEG8000 and PVP40,000 were selected for this study since both were soluble in

water and various organic solvents [79-80]. Selection criteria also involve melting points and
Molecular weights as they are different.
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The solubility was determined at 37 °C in deionized water. The drug concentrations
were determined from the calibration curves analyzed using HPLC. In a physical mixture
of the drug models with PEG 8000 in 1:1, 1:5 and 1:10, the three model drugs showed that
there was no significant enhancement in solubility when compared to the model drug
(p>0.05). However, with all the compositions, the enhancement of solubility was
significant compared to the pure drug (p<0.05).
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Chapter 6: Discussion
The solubility of model drug Glipizide is 11.18 ± 1.78 µg/ml and the physical
mixture with the three ratios in the presence of carriers showed no significance when
compared to the pure drug (p>0.05). However, all the techniques used showed an
enhancement in solubility (p<0.05) when compared to the physical mixture as shown in
table 6. PEG8000 as carrier showed an increase in solubility with an increase in carrier
ratio as shown in Figures 19-21. Fusion method with PEG8000 as a carrier at 1:5 ratio,
showed a 2.28-fold of increase from the physical mixture was observed as the crystallinity
of the drug endothermic peak from DSC thermograph was decreased as shown in Figure
2. There was a decrease in percentage crystallinity to 4.3% with an enthalpy of fusion of 5.2 J/g, when compared to drug enthalpy of -120.8 J/g, which resulted in an increased
solubility. It was observed that there were 1.4-fold of increase in solubility with an enthalpy
of -44.1 J/g and 36 % of crystallinity with the techniques at 1:1 ratio, when compared to
the drug (p<0.05) and significantly observed in Coprecipitation, as shown in Figure 1.
The solubility of Glipizide using nano milling technique, used in 1:1 ratio, increased
the solubility over physical mixture with 2.1 folds with an enthalpy of -4 J/g. In 1:5 ratio,
compared to all methods, nano-milling showed an increase of 3.1 folds when compared to
pure drug and physical mixture, as shown in Figure 2. The particle size reduction took
place in an increased surface area because of the polymer’s effect. The particle sizes were
624nm, 439nm and 633nm for 1:1, 1:5 and 1:10 ratio, respectively. In 1:10 ratio, coprecipitation technique showed an enhanced solubility, as shown in Figure 3. Among the
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ratios, the enhancement in solubility was significant with all the techniques and 1:5 ratio
showed an optimum increase in solubility. Nano-milling showed a high solubility of 35.73
± 0.04 µg/ml, attributing to the reduction of particle size to 439 nm and an absence of
crystallinity was observed in the thermogram. The other possibility was because of the
carrier that helped in preventing recrystallization [81].
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Figure 19. Glipizide Solubility with PEG8000 as Carrier in 1:1 Ratio
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Figure 20. Glipizide Solubility with PEG8000 as Carrier in 1:5 Ratio

Glipizide Solubility with PEG8000 as carrier in 1:10 ratio
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Figure 21. Glipizide Solubility with PEG8000 as Carrier in 1:10 Ratio
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The solubility of Glipizide with PVP40000 as carrier showed enhanced solubility
with the pattern, and it was observed that an increase in carrier ratio leads to a decrease in
solubility. All the techniques showed enhancement in solubility when compared to the drug
and physical mixture with p<0.05 as shown in Figure 22-24. In 1:1 ratio, fusion method
showed a 3-fold increase when compared to the drug. The crystallinity was reduced to 5%
obtained from DSC thermogram with a reduced enthalpy of -5 J/g. Nano-milling showed
significant solubility in 1:1 ratio, when compared to 1:5 and 1:10 ratios as the solubility
increased 3.6 folds when compared to a drug with no crystallinity of drug. It resulted in an
amorphous state with a particle size of 435 nm, which was the lowest size among the ratios.
Among 1:1 ratio, it was observed that fusion method showed an enhanced solubility, as
presented in Figure 4. The co-precipitation method in 1:5 ratio showed an enhanced
solubility where the crystallinity reduced to 7% and enthalpy of -8.7 J/g with an increase
of 3.8 folds from the drug, greater than all the techniques shown in Figure 5. In 1:10 ratio,
among all the techniques, it was observed that 2-fold of increase in solubility occurred with
co-precipitation technique due to the decrease in crystallinity to 8% from drug and the
solubility of technique, as shown in Figure 6.
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Figure 22. Glipizide Solubility with PVP40000 as Carrier in 1:1 Ratio
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Figure 23. Glipizide Solubility with PVP40000 as Carrier in 1:5 Ratio
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Figure 24. Glipizide Solubility with PVP40000 as Carrier in 1:10 Ratio

The solubility of Carvedilol was 5.04 ± 0.55 µg/ml and the solubility of physical
mixtures showed no increase (p>0.05) and was comparable to a pure drug as shown in
Figure 25-27. In 1:1 ratio of PEG8000 as a carrier, fusion method showed an increase of 3
folds and in 1:5 ratio and 1:10 ratios, an increase of 3.4 and 2.5-fold was observed when
compared to the physical mixture, as shown in Figure 7-9. In the nano-milling technique,
the particle size was increasing with a polymer as an agglomeration was taking place. This
led to the decrease in the solubility when compared to drug and physical mixture. In coprecipitation technique, no difference in solubility was observed among the ratio of
carriers. The trend observed was that, due to the absence of drug endothermic peak in the
DSC thermogram, the polymer ratio was not showing any effect on solubility but the
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optimum increase in solubility was found to be with 1:5 ratio with PEG8000 as a carrier.
This states that the reason could be due to the transformation of crystalline from a solid
state to amorphous. Fusion method with 1:5 drug-polymer ratio was observed to be
significant in different ratios to test for solubility of Carvedilol in the presence of PEG8000
as shown in Figure 26.
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Figure 25. Carvedilol Solubility with PEG8000 as Carrier in 1:1 Ratio
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Figure 26. Carvedilol solubility with PEG8000 as Carrier in 1:5 Ratio
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Figure 27. Carvedilol Solubility with PEG8000 as Carrier in 1:10 Ratio
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In the case of Carvedilol with PVP40000 as a carrier, the pattern observed was that
as the ratio of polymer increases, the solubility increases. In 1:1 drug-polymeric ratio,
fusion method showed an increase of 4.6 folds, co-precipitation with 4.8 folds and nanomilling with 0.5 folds of increase, when compared to physical mixture, as shown in Figure
28. It was observed from DSC thermogram that the absence of drug endothermic peak
results in an increase in solubility as the form may be in amorphous as shown in Figure 10.
In 1:5 ratio, the increase in solubility of Carvedilol was observed to be 10.5 folds in nanomilling technique comparable to a physical mixture as shown in Figure 29 whereas, in coprecipitation and fusion method, there were 9 folds and 8 folds of enhancement
respectively, as shown in Figure 11. In 1:10 ratio, 23 folds enhancement of solubility of
the drug with nano milling method, 12 folds with co-precipitation and 9 folds with fusion
method respectively were observed, comparable to the physical mixture, as shown in
Figure 12. The nano-milling technique is more suitable for a polymer with 1:10 ratio of
PVP40000 as the particle size reduced when compared to pure drug shown in Figure 30.
This lead to increase in solubility as there was an increase in particle curvature. The effect
of a change in the solid state also played a vital role as the drug endothermic peak in DSC
thermogram was absent due to the change in crystalline to an amorphous form of the drug.
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Figure 28. Carvedilol Solubility with PVP40000 as Carrier in 1:1 Ratio
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Figure 29. Carvedilol Solubility with PVP40000 as Carrier in 1:5 Ratio
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Figure 30. Carvedilol Solubility with PVP40000 as Carrier in 1:10 Ratio

The solubility of model drug Furosemide was found to be 55.94 ± 2.48 µg/ml. When
physical mixtures were compared to the pure drug, no enhancement in solubility was
observed (p>0.05). There was a trend observed with PEG8000 as a carrier that as the
polymer concentration increased, the solubility of the drug increased. In 1:1 ratio, the
solubility, when compared with drug and physical mixture, presented 1.1, 1.3 and 2.4-fold
increase for fusion method, co-precipitation, and nano-milling techniques respectively, as
shown in Figure 13. In 1:5 ratio, there was 1.2 folds increase with fusion method and coprecipitation as shown in Figure 32. An increase of 2.9-fold in solubility was observed
with nano-milling technique when compared to physical mixture, as shown in Figure 14.
In 1:10 ratio, the increase in solubility was 1.1 folds in fusion and co-precipitation, in

69

contrast to 2.5 folds with the nano-milling technique, as shown in Figure 15. In fusion
method, as the polymer ratio increased, there was solubility enhancement observed in 1:10
ratio as shown in Figure 33. The increase occurred due to the absence of drug crystallinity
determined in thermogram of DSC and the drug could be in an amorphous form. In coprecipitation method, there was no significance observed among the change in the ratio of
the carrier. There was 1.3-fold increase when compared to the drug and physical mixture
in 1:1 ratio as shown in Figure 31. In nano-milling technique, there was an increase in
solubility when compared to drug and physical mixture (p<0.05), where there were 2.9
folds of enhancement observed with 1:10 ratio. This is due to the reduction in the particle
size of the drug, transforming from crystalline form to amorphous form. The particle size
of the drug-polymer ratio was 995 nm, 980 nm, and 929 nm of 1:1, 1:5 and 1:10 ratios
respectively. The particle size of 1:10 ratio was comparatively the lowest among the ratios
with increased solubility.
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Figure 31. Furosemide Solubility with PEG8000 as Carrier in 1:1 Ratio
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Figure 32. Furosemide Solubility with PEG8000 as Carrier in 1:5 Ratio
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Figure 33. Furosemide Solubility with PEG8000 as Carrier in 1:10 Ratio

A decrease in solubility was observed with increase in the ratio of polymer
Furosemide with PVP40000 as a carrier. The physical mixture, when compared to the drug,
was insignificant in solubility whereas all the methods with PVP4000 as a carrier were
significant. In 1:1 ratio, fusion method displayed 2.1-fold, 1.5-fold increase with coprecipitation, 4.9-fold of increase with nano-milling and 2.9-fold increase with spray
drying in solubility when compared to the physical mixture (p<0.05), as shown in Figure
16. In 1:5 ratio, fusion method presented a 1-fold increase in solubility whereas a 4-fold
increase was observed in co-precipitation and nano-milling when compared to physical
mixture, as shown in Figure 17. In 1:10 ratio, there was a 1-fold increase in fusion method,
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2-fold in co-precipitation and 3-fold in nano-milling technique solubility, when compared
to the physical mixture (p<0.05), as shown in Figure 18.
Furosemide at 1:1 ratio with PVP40000 as carrier, presented enhanced solubility
compared to other ratios but in co-precipitation method, 1:5 ratio displayed an
enhancement in solubility shown in Figure 35. Enhanced solubility was significantly
observed in a nano-milling method in 1:1 ratio as it was the effect of particle size reduction
when compared to 1:5 and 1:10 ratios as the particle size were 114 nm, 126 nm, and 132
nm, where the lowest particle size shows significant solubility along with the effect of the
polymer as shown in Figure 34-26. In spray drying method, there was percentage
crystallinity decrease which was observed in 1:1 ratio of DSC thermogram, when compared
to drug percentage crystallinity. This provided an increase in solubility of spray drying
method when compared to the pure drug (p<0.05). The increase in solubility was confirmed
due to the conversion of crystalline form to an amorphous form of the model drug.

73
350

Solubility (µg/ml)

300
250
200
150
100
50
0
Furosemide

Physical mixture Fusion method Co-precipitation

Nano-milling

spray drying

Techniques

Figure 34. Furosemide Solubility with PVP40000 as Carrier in 1:1 Ratio
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Figure 35. Furosemide Solubility with PVP40000 as Carrier in 1:5 Ratio
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Figure 36. Furosemide Solubility with PVP40000 as Carrier in 1:10 Ratio

Among all the techniques, the highest solubility was observed for Furosemide:
PVP40000 (1:1 ratio) 304.52 ± 23.11 µg/ml. This is attributed because of all the techniques,
model drugs and carrier ratios, 1:1 nano-milling technique showed an enhancement in
solubility with the lowest particle size (114nm). The carrier also played a vital role in
wettability of PVP40000, causing more solubility. The thermogram from DSC revealed the
absence of drug endothermic peak, resulting in the change of drug from crystalline to
amorphous form. This helped in the increase of solubility to a greater extent. The lowest
solubility was observed in Carvedilol nano-milling technique with PEG8000 as a carrier
with 1:1 ratio (1.95 ± 0.21 µg/ml). This attributes to the reason that the carrier was not
providing stabilization of the drug molecules from recrystallizing. Particle agglomeration
occurred as the particle size increased from than that of pure drug. The increase in particle
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size led to a delay of solubility, which caused least interactions with the carrier and aqueous
environment. Similarly, among each model drug, the carrier and technique with a change
in ratio showed the effect of enhancement of solubility and the percentage enhancement
was shown in table 7. It could be because of the better miscibility of the model drug in the
polymeric carrier in these techniques that depended on the solid-state transitions.
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Table 7. Percentage Enhancement of Aqueous Solubility Compared to the Drug
Percentage

PEG8000

PVP40000

enhancement
Composition Ratio Glipizide Carvedilol Furosemide Glipizide Carvedilol Furosemide
(%)

(%)

(%)

(%)

(%)

(%)

Fusion

1:1

15

220

14

286

484

136

method

1:5

128

246

23

250

857

129

1:10

120

151

36

78

1138

80

Co-

1:1

141

135

33

126

384

67

precipitation

1:5

146

121

29

284

959

402

1:10

216

129

30

104

1969

244

Nano-

1:1

112

-61

141

261

-44

444

milling

1:5

219

-59

192

178

1105

413

1:10

115

-57

193

-26

2929

315

Spray

1:1

-

-

-

42

-

226

Drying

1:10

-

-

-

-

1237

-

Summary
Solubility enhancement of 3 model drugs with selected carriers was performed by
fusion method, co-precipitation, nano-milling and Spray drying techniques, at 3 ratios of
carriers. PEG8000 enhanced the solubility for Glipizide was achieved 128 % by fusion
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method at 1:5 ratio, 216 % by coprecipitation at 1:10 ratio and 219 % by nano-milling
method at 1:5 ratio, while PVP enhanced the solubility by 286% by fusion at 1:1 ratio,
284% by co-precipitation at 1:5 ratio, 261 % by nano-milling method at 1:1 ratio and 42 %
by Spray drying at 1:1 ratio. PEG8000 enhanced solubility of Carvedilol was achieved 246
% by fusion method at 1:5 ratio, 135 % by coprecipitation at 1:1 ratio but decrease in
solubility by 61 % by nano-milling method at 1:1 ratio, while PVP enhanced the solubility
by 1138 % by fusion at 1:10 ratio, 1969 % by co-precipitation at 1:10 ratio, 2929 % by
nano-milling method at 1:10 ratio and 1237% by Spray drying method at 1:10 ratio.
PEG8000 enhanced the solubility for Furosemide was achieved 36 % by fusion method at
1:10 ratio, 33 % by coprecipitation at 1:1 ratio and 193 % by nano-milling methods at 1:10
ratio, while PVP enhanced the solubility by 136 % by fusion at 1:1 ratio, 402 % by coprecipitation at 1:5 ratio, 444 % by nano-milling method at 1:1 ratio and 226% by Spray
drying method at 1:1 ratio. The results indicated that the change in the melting temperature
and enthalpy of the thermograph along with the particle size reduction leading to solidstate transitions of crystalline to amorphous forms resulted in an increase in solubility. The
percentage of crystallinity depending upon the polymer used resulting in enhancement of
the model drugs aqueous solubility.
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Chapter 7: Conclusion
Several techniques were applied to determine the enhancement of solubility among
which this study relied on fusion method, co-precipitation, nano-milling and spray drying
techniques. The increase in aqueous solubility over the physical mixtures indicated that the
techniques improved the solubility of the drug. This can be applied to the model drugs with
different structural and properties under a defined range of experimental conditions.
The first objective of this dissertation was to prepare the mentioned model drugs
using PEG8000 and PVP40000 in 1:1, 1:5 and 1:10 drug-polymeric ratios. The
compositions were compared to physical mixtures, to determine the increase in solubility
which successfully enhanced by the techniques over the physical mixture and drug
(p<0.05) except carvedilol with nano-milling technique. The parameters except the model
drugs were kept constant and solubility was quantified with HPLC.
The solubility of Glipizide has been enhanced from 11.18 ± 1.78 µg/ml to 43.26
±7.87 µg/ml by fusion method in 1:1 ratio. The solubility of Carvedilol was enhanced from
5.04 ± 1.22 µg/ml to 152.70 ± 9.09 µg/ml by 1:10 ratio with nano-milling technique and
the solubility of Furosemide was enhanced from 55.94 ± 2.48 µg/ml to 304.52 ± 23.11
µg/ml with 1:1 ratio using the nano-milling technique with the influence of decrease in
particle size. The enhancement of solubility depended on enthalpy decrease from the pure
drug with the possibility of conversion of crystalline form to amorphous solid-state
transition. With this, the second objective was successfully achieved.
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The third objective was to determine the method of each model drug that showed
significant enhancement in solubility. For Glipizide, the enhancement of solubility was
achieved with 1:1 ratio using PVP40,000 with all the techniques, among which fusion
method showed enhancement in solubility. Hence, 1:1 drug-polymer ratio is suitable for
the ratios and fusion method is the most suitable technique for Glipizide to increase
solubility. The solubility of Carvedilol was significant with 1:10 ratio by nano-milling
technique and the solubility of Furosemide had increased with 1:1 ratio by nano-milling
technique. Hence, this study reports the suitable techniques for enhancement of solubility
with an optimum polymeric ratio that can be used in early stages to estimate solubility
enhancement of model drugs subjected to fusion method, co-precipitation, nano-milling
and spray drying techniques.
All the techniques, except nano-milling exhibited solubility enhancement with
PVP40000 and PEG8000, with optimum ratios for each model drug. There was a decrease
in solubility with PEG8000 as the carrier at all ratios in nano-milling of Carvedilol, whereas
with PVP40000 as the carrier, the decrease in solubility was observed at 1:10 ratio of
Glipizide and 1:1 ratio of Carvedilol with nano-milling technique. In conclusion, although
nano-milling technique showed the decrease in solubility with certain drugs and polymer
ratios due to agglomeration as one of the drawbacks, all the other techniques showed
significance in solubility with all the model drugs at 1:1, 1:5 and 1:10 ratios with PEG8000
and PVP40000 as carriers. The enthalpy decreased for all the composites when compared
to the pure drug, resulting in enhancement of solubility.
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